Physician profile
James Willard Byrd
NPI 1730191701
$3,289.06
in general payments reported to CMS, 2019-2025
20 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $299 · 2021: $441 · 2022: $903 · 2023: $560 · 2024: $327 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960 · Education: $49.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.67 |
| Education | $49.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,432.09 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $264.22 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.82 | 2020-2023 | |
| Abbvie INC. | $192.41 | 2021-2023 | Vraylar |
| Sunovion Pharmaceuticals INC. | $187.29 | 2019-2022 | |
| Alkermes, INC. | $186.79 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $139.32 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.24 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $91.22 | 2022-2023 | Austedo |
| Vanda Pharmaceuticals INC. | $86.74 | 2019-2022 | |
| Axsome Therapeutics, INC. | $79.07 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $56.19 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.18 | 2023 | Abilify Maintena |
| Lundbeck LLC | $38.46 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $28.33 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22.47 | 2020 | |
| Merck Sharp & Dohme LLC | $14.12 | 2022 | |
| Allergan, INC. | $13.96 | 2019 | |
| Acadia Pharmaceuticals INC | $13.39 | 2019 | |
| Indivior INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.